 DecisionBase PDFs --
2008
 Overview:
Hypertension, known as the "silent killer," is the most
prevalent cardiovascular disease in the Western world. It is the major risk
factor for coronary heart disease, heart failure, and stroke and has more than
72 million sufferers in the United States alone. Marked by an abundance of
effective agents with a wide range of mechanisms of action, the market for
hypertension is highly competitive. Despite an array of effective medications, good
control of blood pressure remains an elusive goal. Moreover, poor patient
compliance and requisite polypharmacy for treating the disease leave
significant drug development opportunity. Physicians and pharmaceutical
companies alike are increasingly turning to fixed-dose combinations to treat
hypertension and aid patient compliance.
Questions Answered in This Report:
 A drug’s performance on at least six efficacy end points,
including reduction in all-cause mortality and reduction in the incidence of
cardiovascular events, is important for drug approval and physician use. What
are the key primary and secondary clinical trial end points with which new
therapies are evaluated? How do primary care physicians weight efficacy
measures and other drug attributes in their prescribing decisions for
hypertension?
Amlodipine (Pfizer’s Norvasc, Dainippon Sumitomo’s Amlodin,
generics) is the 2006 major-market sales leader for hypertension. Do thought
leaders expect emerging therapies to offer significant improvements in efficacy,
safety and tolerability, or delivery over amlodipine? Which emerging therapies
pose the greatest threat to amlodipine?
Based on its clinical profile, amlodipine/valsartan
(Novartis’s Exforge) is the 2006 clinical gold standard in our drug comparator
model. What attributes do thought leaders believe differentiate this drug from
competing current and emerging therapies? Will any drugs in development
challenge amlodipine/valsartan as the future gold standard in 2011 or 2016?
Scope:
Key drug development opportunity tested in our target
product profiles for hypertension: An oral drug that reduces left ventricular
hypertrophy (LVH; left ventricular mass index) significantly more than
valsartan for the treatment of hypertension.
Physicians surveyed for this study: 60 U.S. primary care physicians.
Comprehensive List of Therapies Included in Our Research and
Modeling
Current therapies:
- Amlodipine (Pfizer’s Norvasc, Dainippon Sumitomo’s Amlodin,
generics)
- Valsartan (Novartis’s Diovan/Tareg)
- Ramipril (King’s Altace, Sanofi-Aventis’s Triatec, generics)
- Aliskiren (Novartis’s Tekturna/Rasilez)
- Amlodipine/valsartan (Novartis’s Exforge)
Emerging therapies:
- Darusentan (Gilead)
- Ilepatril (Sanofi-Aventis)
- Aliskiren/valsartan (Novartis)
- Aliskiren/hydrochlorothiazide (Novartis’s Tekturna HCT)
About DecisionBase
Hypertension: Many Treatment Options, but None Stands Out in
the Efficacy Measures Most Important to PCPs is a DecisionBase 2008 study from
Decision Resources. DecisionBase 2008 combines market forecasts with clinical
and commercial end points to assess market share projections in 35 indications.
These outputs are driven by quantitative and qualitative primary research.
DecisionBase 2008 provides detailed market share, patient share, and
price-per-day projections for emerging drugs in development. The market share
projections are based on prescriber surveys that compare physicians’
expectations of a potential target product profile with an emerging product
profile of the leading drugs in development.
|
